Phio Pharmaceuticals CorpNASDAQ:PHIO
- LAST PRICE5.7105
- TODAY'S CHANGE (%)-0.0795 (-1.3731%)
- Bid / Lots5.3500/ 3
- Ask / Lots6.8900/ 10
- Open / Previous Close5.7106 / 5.7900
- Day Range
- 52 Week Range
- Volume6,437
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHIO |
|---|---|---|
| 10:19 ET | 225 | 5.7106 |
| 11:58 ET | 100 | 5.8 |
| 01:28 ET | 449 | 5.56 |
| 01:33 ET | 1000 | 5.6307 |
| 01:39 ET | 1600 | 5.83 |
| 01:42 ET | 912 | 5.91 |
| 03:36 ET | 941 | 5.7105 |
Mar 22, 2023
BRIEF-Phio Pharmaceuticals Posts FY Loss Of $10.10 Per Share , from 5:09PM ET on Wednesday Mar 22, 2023 by Thomson Reuters
5:09PM ET on Wednesday Mar 22, 2023 by Thomson ReutersPhio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update, from 5:05PM ET on Wednesday Mar 22, 2023 by PR Newswire
5:05PM ET on Wednesday Mar 22, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Phio Pharmaceuticals Corp | 6.6M | -0.6x | --- |
OncoSec Medical Inc | 6.6M | -0.2x | --- |
X T L Biopharmaceuticals Ltd | 6.4M | -2.1x | --- |
Eloxx Pharmaceuticals Inc | 6.9M | -0.1x | --- |
GB Sciences Inc | 6.9M | -1.1x | --- |
Aclarion Inc | 6.5M | 0.0x | --- |
Company Information
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL-based therapeutics are used to strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT) and directly modify cells in the tumor microenvironment (the TME) to weaken a tumors defense. Its lead product candidate is PH-762, which is an INTASYL compound that activates immune cells to better recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1, a clinically validated target for immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression that impacts cell differentiation, and hence, cell function. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.
Contact Information
- Headquarters
- 257 Simarano Dr Ste 101MARLBOROUGH, MA, United States 01752-3070
- Phone
- 508-767-3861
- Fax
- 508-767-3862
Executives
- Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
- Robert Bitterman
- Independent Director
- Patricia Bradford
- Independent Director
- Geert Cauwenbergh
- Independent Director
- H. Paul Dorman
- Independent Director
- Robert Ferrara
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-10.10 |
Book Value | $9.52 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
